Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
26. November 2024 07:45 ET
|
Profound Medical Corp.
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Participate in the Stifel 2024 Healthcare Conference
12. November 2024 08:00 ET
|
Profound Medical Corp.
TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Third Quarter 2024 Financial Results
07. November 2024 16:05 ET
|
Profound Medical Corp.
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
04. November 2024 06:55 ET
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...
Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow
17. Oktober 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
16. Oktober 2024 16:15 ET
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
01. Oktober 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Koelis Announces New Compact 3D Probe to Improve Workflow and Reprocessing
25. September 2024 09:07 ET
|
Koelis
Koelis is pleased to announce the introduction of our new 3D ultrasound probe that maximizes auto reprocessing compatibility.
Koelis Announces Partnership and Initial Experience with DeepHealth for AI-powered Prostate MRI Interpretation and Guidance in Fusion Biopsy
20. September 2024 09:07 ET
|
Koelis
Koelis finalizes partnership with Deep Health for AI-powered prostate MRI interpretation and guidance in fusion biopsy for prostate cancer.
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
10. September 2024 04:30 ET
|
Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN